Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

NCT04799353 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG: Budigalimab
DRUG: Placebo
DRUG: Budigalimab
DRUG: Placebo

Sponsor

AbbVie